439 related articles for article (PubMed ID: 26102213)
1. Hepatic Steatosis as a Marker of Metabolic Dysfunction.
Fabbrini E; Magkos F
Nutrients; 2015 Jun; 7(6):4995-5019. PubMed ID: 26102213
[TBL] [Abstract][Full Text] [Related]
2. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.
Fabbrini E; Sullivan S; Klein S
Hepatology; 2010 Feb; 51(2):679-89. PubMed ID: 20041406
[TBL] [Abstract][Full Text] [Related]
3. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.
Fabbrini E; Mohammed BS; Magkos F; Korenblat KM; Patterson BW; Klein S
Gastroenterology; 2008 Feb; 134(2):424-31. PubMed ID: 18242210
[TBL] [Abstract][Full Text] [Related]
4. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
Fernandes GW; Bocco BMLC
Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
[TBL] [Abstract][Full Text] [Related]
5. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
[TBL] [Abstract][Full Text] [Related]
6. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice.
Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH
J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease.
Smith GI; Shankaran M; Yoshino M; Schweitzer GG; Chondronikola M; Beals JW; Okunade AL; Patterson BW; Nyangau E; Field T; Sirlin CB; Talukdar S; Hellerstein MK; Klein S
J Clin Invest; 2020 Mar; 130(3):1453-1460. PubMed ID: 31805015
[TBL] [Abstract][Full Text] [Related]
8. iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling.
Deng X; Wang J; Jiao L; Utaipan T; Tuma-Kellner S; Schmitz G; Liebisch G; Stremmel W; Chamulitrat W
Biochim Biophys Acta; 2016 May; 1861(5):449-61. PubMed ID: 26873633
[TBL] [Abstract][Full Text] [Related]
9. Metabolic-associated fatty liver disease and lipoprotein metabolism.
Heeren J; Scheja L
Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
[TBL] [Abstract][Full Text] [Related]
10. Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.
Alves-Bezerra M; Li Y; Acuña M; Ivanova AA; Corey KE; Ortlund EA; Cohen DE
Hepatology; 2019 Aug; 70(2):496-510. PubMed ID: 30516845
[TBL] [Abstract][Full Text] [Related]
11. Modulation of hepatic steatosis by dietary fatty acids.
Ferramosca A; Zara V
World J Gastroenterol; 2014 Feb; 20(7):1746-55. PubMed ID: 24587652
[TBL] [Abstract][Full Text] [Related]
12. Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD.
Vacca M; Allison M; Griffin JL; Vidal-Puig A
Semin Liver Dis; 2015 Aug; 35(3):250-61. PubMed ID: 26378642
[TBL] [Abstract][Full Text] [Related]
13. Fructose as a key player in the development of fatty liver disease.
Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
[TBL] [Abstract][Full Text] [Related]
14. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes.
Carlier A; Phan F; Szpigel A; Hajduch E; Salem JE; Gautheron J; Le Goff W; Guérin M; Lachkar F; Ratziu V; Hartemann A; Ferré P; Foufelle F; Bourron O
Cell Rep Med; 2020 Dec; 1(9):100154. PubMed ID: 33377125
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
Milić S; Lulić D; Štimac D
World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
[TBL] [Abstract][Full Text] [Related]
16. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals.
Saponaro C; Sabatini S; Gaggini M; Carli F; Rosso C; Positano V; Armandi A; Caviglia GP; Faletti R; Bugianesi E; Gastaldelli A
Liver Int; 2022 Nov; 42(11):2418-2427. PubMed ID: 35900229
[TBL] [Abstract][Full Text] [Related]
17. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
[TBL] [Abstract][Full Text] [Related]
19. Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.
Poulsen MK; Nellemann B; Stødkilde-Jørgensen H; Pedersen SB; Grønbæk H; Nielsen S
J Clin Endocrinol Metab; 2016 Apr; 101(4):1637-46. PubMed ID: 26829441
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
Pafili K; Roden M
Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
